China plans comprehensive reform of drug regulations

02/27/2013 | Regulatory Focus

China's State Food and Drug Administration has announced plans for wide-ranging changes in its drug regulatory process. The plan will foster research and development through a more favorable regulatory environment; update the national strategy for generic drugs; boost the quality of pharmaceutical clinical trials and how they are managed; and encourage the creation of more pediatric pharmaceuticals.

View Full Article in:

Regulatory Focus

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD